Novo Nordisk A/S $NVO Shares Acquired by Focus Partners Wealth

Focus Partners Wealth boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 11.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 844,234 shares of the company’s stock after acquiring an additional 83,619 shares during the quarter. Focus Partners Wealth’s holdings in Novo Nordisk A/S were worth $43,105,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of NVO. Aurora Investment Counsel increased its position in shares of Novo Nordisk A/S by 14.8% in the fourth quarter. Aurora Investment Counsel now owns 44,385 shares of the company’s stock valued at $2,258,000 after buying an additional 5,706 shares in the last quarter. Avidity Partners Management LP purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $3,424,000. Brown Advisory Inc. increased its position in shares of Novo Nordisk A/S by 5.8% in the fourth quarter. Brown Advisory Inc. now owns 113,301 shares of the company’s stock valued at $5,765,000 after buying an additional 6,261 shares in the last quarter. Aigen Investment Management LP purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $861,000. Finally, Altrafin AG purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $8,913,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on NVO shares. The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a research report on Tuesday, March 10th. Wolfe Research started coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Finally, Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $43.85 on Tuesday. The firm has a market capitalization of $195.81 billion, a P/E ratio of 10.29, a P/E/G ratio of 3.92 and a beta of 0.78. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $78.38. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The business’s 50-day simple moving average is $42.42 and its 200-day simple moving average is $45.98.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities analysts predict that Novo Nordisk A/S will post 3.45 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.